{
    "Trade/Device Name(s)": [
        "Access Total \u03b2hCG (5th IS)"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K221990",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130020"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHA"
    ],
    "Summary Letter Date": "July 5, 2022",
    "Summary Letter Received Date": "July 6, 2022",
    "Submission Date": "July 5, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1155"
    ],
    "Regulation Name(s)": [
        "Human Chorionic Gonadotropin (hCG) Test System"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Total \u03b2hCG"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Paramagnetic particle assay",
        "Automated",
        "Two-step sandwich"
    ],
    "Methodologies": [
        "Chemiluminescent immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Beckman Coulter Access Total \u03b2hCG (5th IS) chemiluminescent immunoassay for early detection of pregnancy",
    "Indications for Use Summary": "For quantitative determination of total \u03b2hCG levels in human serum and plasma as an aid in the early detection of pregnancy",
    "fda_folder": "Clinical Chemistry"
}